As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.
25 Analysts have issued a arGEN-X forecast:
25 Analysts have issued a arGEN-X forecast:
Jun '25 |
+/-
%
|
||
Revenue | 2,594 2,594 |
-
|
|
Gross Profit | 2,319 2,319 |
-
|
|
EBITDA | 416 416 |
-
|
EBIT (Operating Income) EBIT | 397 397 |
-
|
Net Profit | 1,089 1,089 |
-
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Head office | Netherlands |
CEO | Tim Hauwermeiren |
Employees | 1,599 |
Founded | 2008 |
Website | www.argenx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.